In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011 Scrip 100: Will Dilma be good for pharma?

This article was originally published in Scrip

Executive Summary

Luiz Inacio Lula da Silva (Lula) will step down as President of Brazil in January 2011 after steering his country into a new era of stability and prosperity. Now, as his protégé Dilma Rousseff prepares to take over, there is a wide expectation amongst those same commentators that she will continue the fiscally-responsible strategies of her mentor. Mark Hollis examines the likely implications for the pharmaceutical industry.

You may also be interested in...



1-2-300! The biosimilar horde stands at the gate

Despite claims from 'research-based' biologics manufacturers and their representatives in the EU and US that the biosimilars market is small and relatively unimportant, the age of biosimilars is clearly already upon us. A recently launched database from Datamonitor reveals a total of 556 biosimilars currently in development or being marketed globally with over 200 companies involved in the endeavour.

UK Budget good for large corporates and academia, but little for biotechs

The UK Chancellor of the Exchequer [finance minister] George Osborne assured Parliament on 21 March that he would be backing industries such as pharmaceuticals, amongst others, in an effort to reduce the dominance of the financial services industry.

Biosimilars regulation in emerging markets

Mark Hollis explores developments in emerging markets and considers what their impact might be on growth.

Topics

Related Companies

UsernamePublicRestriction

Register

SC011273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel